4 completed, 2 recruiting, 2 terminated. 5 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Recruiting 2, Terminated 1 |
| Phase 1 | 4 | Completed 3, Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow AL001: new trials by email Literature Review of AL001 trials Research Report on AL001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder AL001, Lithium carbonate - Bipolar I Disorder | Phase 1 / Phase 2 | Recruiting | Alzamend Neuro, Inc. | 20 | 2026-05-11 | 2026-07-28 |
| A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects AL001, Lithium Carbonate Capsule - Pharmacokinetics, Neurology | Phase 1 | Completed | Alzamend Neuro, Inc. | 15 | 2025-05-09 | 2026-07-29 |
| Continuation Study for Latozinemab Latozinemab - Neurodegenerative Diseases | Phase 3 | Terminated | Alector Inc. | 17 | 2023-12-08 | 2026-01-21 |
| Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer Cadonilimab, Anlotinib, Granulocyte-Macrophage Colony-Stimulating Factor - Cervical Cancer | Phase 2 | Recruiting | Zhongnan Hospital | 35 | 2023-02-16 | 2024-04-19 |
| Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects AL001, Placebo - Alzheimer's Disease, Healthy Non-elderly and Elderly Adults | Phase 1 / Phase 2 | Completed | Alzamend Neuro, Inc. | 65 | 2022-05-04 | 2025-05-14 |
| A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS AL001, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Terminated | Alector Inc. | 5 | 2021-09-02 | 2025-06-18 |
| A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) AL001 - Frontotemporal Dementia | Phase 2 | Completed | Alector Inc. | 33 | 2019-09-27 | 2025-12-05 |
| A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation AL001, Placebo - Healthy, Frontotemporal Dementia | Phase 1 | Completed | Alector Inc. | 64 | 2018-09-14 | 2020-07-27 |
Frontotemporal Dementia (3) · Amyotrophic Lateral Sclerosis (2) · Alzheimer Disease (1) · Neurodegenerative Diseases (1) · Uterine Cervical Neoplasms (1)
Alector Inc. (4) · Alzamend Neuro, Inc. (3) · Zhongnan Hospital (1)
United States (7) · Canada (4) · United Kingdom (3) · Germany (2) · Italy (2) · Netherlands (2) · Belgium (1) · China (1) · France (1) · Portugal (1) · Sweden (1)
Eric Sicard, MD (1) · George Stoica (1) · Hui Qiu, Ph.D. (1) · Peter Ljubenkov, MD (1) · Sabrina Paganoni, MD (1)
2023 (1)